Sihuan Pharma Subsidiary Xuanzhu's Bireociclib Gains China Reimbursement for First-Line Breast Cancer TreatmentPUBT·Nov 16, 2026 at 08:40 AM02575-4.74%00460-1.94%
Weekly Recap | SIHUAN PHARM -0.64%, consensus target above spotWeekly Review·Nov 14, 2026 at 05:34 AM00460-1.94%
Weekly Recap | SIHUAN PHARM +11.89%, consensus target above spotWeekly Review·Nov 7, 2026 at 06:14 AM00460-1.94%
Niche Breakthroughs Power Hong Kong's Forgotten Small-CapsGlobal Report·Oct 28, 2026 at 09:20 AM02378-0.15%00467-1.20%
Nine Hong Kong Small Caps Filed at Once. The Income Statement Moved FirstGlobal Report·Oct 28, 2026 at 03:46 AM020160.00%02290+3.34%
Weekly Recap | SIHUAN PHARM +6.38%, aesthetics approvals and trial winWeekly Review·Oct 24, 2026 at 05:31 AM00460-1.94%
Xuanzhu Biopharmaceutical’s Anaprazole Sodium Meets Primary Endpoint in Phase III Reflux Esophagitis TrialPUBT·Oct 21, 2026 at 12:54 PM02575-4.74%
Weekly Recap | SIHUAN PHARM -0.7%, consensus target sits above spotWeekly Review·Oct 17, 2026 at 05:59 AM00460-1.94%
The Signal for Hong Kong's Leftover Small Caps Comes From AbroadGlobal Report·Oct 13, 2026 at 10:51 AM02668-1.79%02552-0.24%
Weekly Recap | SIHUAN PHARM +4.23%, medical aesthetics pushWeekly Review·Oct 10, 2026 at 05:39 AM00460-1.94%
Sihuan Pharmaceutical Invests in Canton Biologics to Build Full-Chain Regenerative Aesthetics PlatformTip Ranks·Oct 8, 2026 at 01:08 PM00460-1.94%
Weekly Recap | SIHUAN PHARM flat, consensus target 177% above spotWeekly Review·Oct 3, 2026 at 08:16 AM00460-1.94%
Niche Hong Kong Stocks Navigate Policy Shifts Through Beauty, Project Management, and Control TransfersGlobal Report·Sep 29, 2026 at 09:15 AM00460-1.94%002180.00%